Gilead and Arcellx Present Promising CAR-T Therapy Data for Advanced Multiple Myeloma, Highlighting Safety and Efficacy Against Carvykti

Gilead, Arcellx, CAR-T therapy, multiple myeloma, anito-cel, Carvykti, ASH 2024, safety profile, efficacy, relapsed/refractory multiple myeloma

Exsilio Therapeutics Launches with $82 Million to Develop mRNA-Based Genomic Medicines Under Tal Zaks’ Leadership

Exsilio Therapeutics, mRNA, genomic medicines, Tal Zaks, gene therapy, gene editing, lipid nanoparticle delivery, redosing, safety profile, gene therapy approval